4-phenylbutyric acid has been researched along with Dysmyelopoietic Syndromes in 3 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maslak, P | 1 |
| Chanel, S | 1 |
| Camacho, LH | 1 |
| Soignet, S | 1 |
| Pandolfi, PP | 1 |
| Guernah, I | 1 |
| Warrell, R | 1 |
| Nimer, S | 1 |
| Ryningen, A | 1 |
| Stapnes, C | 1 |
| Bruserud, Ø | 1 |
| List, AF | 1 |
1 review available for 4-phenylbutyric acid and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
Topics: Amifostine; Cell Differentiation; Clinical Trials as Topic; Cytoprotection; Hematopoiesis; Humans; M | 1998 |
1 trial available for 4-phenylbutyric acid and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acetylation; Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aza | 2006 |
1 other study available for 4-phenylbutyric acid and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell C | 2007 |